India Must Call US Bluff On Pharmaceuticals


Indian drug makers are expected to adhere to norms in the US, one of their key markets, so why aren’t US companies operating in India following the laws here?

Apart from the deterioration of the business environment in general, which impacts both domestic and foreign investors, retrospective taxation has figured most prominently in the media as the principal cause of growing scepticism among foreign investors. Entirely missing from the discourse has been an equally potent factor with wholly foreign origins: the hijacking of the economic policy dialogue between the United States and India by pharmaceutical lobbies in the US.

Read the source article at Business Standard

About the Author

Leave a Reply